|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Caspase-3 Inhibitor III>> Market Analysis Reports |
Market Analysis Reports of Caspase-3 Inhibitor III |
|
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2018 Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'Caspase 3 - Pipeline Review, H2 2018'; Caspase 3 (Apopain ... Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2018 Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2018 ... Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018 Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018 SUMMARY Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE ... C-Raf Kinase Inhibitor– Pipeline Insight, 2020 ... , C-Raf delays differentiation by inhibiting caspase activation. In epidermal development, C-Raf ... compound developed by Metagone. It is a C-Raf inhibitor, which demonstrates inhibition effect on ... (Phase II and Phase II/III) Early-stage products (Phase I/II ... Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment ... Proteasome inhibitors - Pipeline Insight, 2022 ... hyperactivation of the trypsin-like (?2) and caspase-like (?1) proteolytic sites to compensate for ... molecule proteasome inhibitor (PI). It is approved for multiple myeloma. It is currently in Phase III stage of development ... MALT1 protein inhibitor - Pipeline Insight, 2022 ... is a paracaspase, which is related to the caspase (cysteine-aspartic proteases) family of proteases ... treat/improve MALT1 protein inhibitors. MALT1 protein inhibitors Emerging Drugs Chapters ... like Late stage products (Phase III) Mid-stage products (Phase II) ... Caspases Inhibitor -Pipeline Intelligence, 2019 ... within 1-2 Business Days. CmaxInsight’s, “Caspases Inhibitor-Pipeline Intelligence, 2019”, report ... NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical ... and opportunities that influence Caspases Inhibitor R&D Please note: Certain sections in ... Bcl 2 Like Protein 1 - Pipeline Review, H2 2019 ... family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death ... preventing the release of the caspase activator (CYC1) from the ... molecules developed by companies in Phase III, Phase II and Preclinical stages ... Apoptosis: Market Research Report This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the ... Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update ... family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death ... preventing the release of the caspase activator (CYC1) from the ... molecules developed by companies in Phase III, Phase II, Phase I and Preclinical ... Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021 ... family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulates cell death ... preventing the release of the caspase activator (CYC1) from the ... molecules developed by companies in Phase III, Phase II, Phase I and Preclinical ... Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Drugs in Development by Stages, Target, MoA, RoA, ... Bcl 2 Like Protein 1 - Pipeline Review, H1 2020 ... family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death ... preventing the release of the caspase activator (CYC1) from the ... molecules developed by companies in Phase III, Phase II, Phase I and Preclinical ... Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019 Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H2 2019 SUMMARY Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein ... Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2020 Mitogen Activated Protein Kinase Kinase Kinase 5 - Pipeline Review, H1 2020 SUMMARY Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Mitogen-activated protein ... Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022 ... |